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The development of immortalized cell lines has been a significant benefit to the study of human disease, due to limitations in using
primary cells and the availability of tissue. The immortalization of cells from cystic fibrosis (CF) patients as well as cells from non-CF
individuals from tissues relevant to CF has been critical to enhancing our understanding of the physiological, biochemical and genetic
mechanisms underlying CF and for the development of therapeutic strategies designed to manage CF pathology. A comprehensive list of
immortalized cells from various tissue and species, with an emphasis on epithelial cells, is presented and discussed here.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cell lines; Immortalization; CF cellular models1. Introduction
The development of immortalized cell lines has been a
significant benefit to the study of human disease [1–3].
This has been particularly relevant to the analysis of
inherited diseases such as cystic fibrosis (CF) where the
paucity of material provided by tissue and primary cell
systems limits studies of the CF defect, including bio-
chemical and metabolic correlations with disease patholo-
gy. The immortalization of cells from CF patients as well
as cells from non-CF individuals from tissues relevant to
CF has been critical to enhancing our understanding of the
physiological, biochemical and genetic mechanisms under-
lying CF and for the development of therapeutic strategies
designed to manage CF pathology. Immortalized epithelial
cells from various tissue and species (Table 1) have
played a significant role in advancing our knowledge of
CF. However, the airway epithelium has been the primary
tissue target for the development of immortalized cells
because of its relationship to CF morbidity and mortality.1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.040
Abbreviations: EBV, Epstein-Barr virus; HPV, human papilloma virus;
hTERT, human telomerase; LT, large T-antigen; SV40, simian virus 40.
* Corresponding author. California Pacific Medical Center Research
Institute, Stern Building, Room 106, 2330 Clay Street, San Francisco, CA
94115, USA. Tel.: +1-415-600-1362; fax: +1-415-600-1390.
E-mail address: dieter@cooper.cpmc.org (D.C. Gruenert).While the emphasis for the immortalization of cells for CF
research has been on epithelial cells in general, immortal-
ized CF lymphocytes have provided an invaluable re-
source for genetic screening of large numbers of CF
patients.
Immortalized airway epithelial cells have been particu-
larly instrumental in providing a means to more fully
characterize the relationship between the Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) gene and
disease phenotype. In addition, these cells have been critical
in the development of genetic and pharmacological thera-
pies and are key to high-through-put screening strategies
now being employed to identify new drugs for the treatment
of CF. There have been multiple approaches taken to
achieve airway epithelial cell immortalization, including
simian virus 40 (SV40) large T-antigen (SV40-LT)- based
(both non-temperature sensitive and temperature sensitive)
[2–5], adeno-SV40 hybrid virus [6,7], human papilloma
virus (HPV)-based [8], and a system based on the intro-
duction of SV40-LT and human telomerase (hTERT) trans-
genes [9,10]. However, because most of the immortalized
cell lines were derived through transformation with SV40
based systems, the primary emphasis of the discussion will
focus on the development of cell lines using these systems.
One approach that has been particularly effective has
employed the origin-of-replication defective SV40 plasmid
(pSVori-) [1,2].ed by Elsevier B.V. All rights reserved.
Table 1
List and details of cell lines used in CF research
Name/code Origin/line Cell type Species Transgene
(promoter)
or genotype
Immortalization Transepithelial
resistance
(V cm2)
Description/comments Contact
NCF3 Airway CF H none AdE1/SV40 f 350 F508DELdel Bob Scholte, Erasmus
University, The Netherlands
IEC-6 Intestinal crypt R none Spontaneous no Crypt stem cell type ATCC
IEC-CF7 IEC-6 Intestinal crypt R hCFTR (MLV LTR) Spontaneous no Transfection/selection Bob Scholte, Erasmus
University, The Netherlands
NIH 3T3 Mouse fibroblast M wt CFTR no Transfection/selection M.J. Welsh, U. of Iowa
NIH 3T3 Mouse fibroblast M F508del CFTR no Transfection/selection M.J. Welsh, U. Iowa
CHO Ch hamster ovary CH wt CFTR no Transfection/selection J.R. Riordan, Mayo
CHO Ch hamster ovary CH F508del CFTR no Transfection/selection J.R. Riordan, Mayo
L cell M wt CFTR no Retroviral transduction J.M. Wilson, U. Pennsylvania
L cell M F508del CFTR no Retroviral transduction J.M. Wilson, U. Pennsylvania
C127 wt CFTR no Transfection/selection S. Cheng, Genzyme
C127 F508del CFTR no Transfection/selection S. Cheng, Genzyme
HEK-Flp wt CFTR no Transfection/selection N.A. Bradbury, U. Pittsburgh
HEK-Flp F508del CFTR no Transfection/selection N.A. Bradbury, U. Pittsburgh
Calu-3 Calu-3 Serous epith. H wt CFTR Adenocarcinoma f 300 ATCC
T84 T84 Colonic epith. H wt CFTR Adenocarcinoma f 1000 ATCC
HT29 Cl.19A HT29 Cl.19A Colonic epith. H wt CFTR Adenocarcinoma f 200 ATCC
IB3-1 IB3-1 CF bronchial H F508del/W1282X AdV12/SV40 no Immortalized P.L. Zeitlin, Johns Hopkins U.
S9 IB3-1 H wt CFTR AdV12/SV40 no Ditto
CFPAC-1 CFPAC-1 Pancreatic epithelial H Null control Adenocarcinoma 300-800 Parental pancreatic R.A. Frizzell, U. Pittsburgh
CFPAC-1 H wt CFTR inferred from
parental
Retroviral transduction R.A. Frizzell, U. Pittsburgh
CFPAC-1 H F508del CFTR inferred from
parental
Retroviral transduction R.A. Frizzell, U. Pittsburgh
Fisher Rat
Thyroid
Thyroid carcinoma R wt CFTR >1000 Transfection/selection M.J. Welsh, U. Iowa
FRT Thyroid carcinoma R F508del CFTR >1000 Transfection/selection M.J. Welsh, U. Iowa
AA Bronchial cells H wt CFTR hTERT /SV40 LT f 150 Immortalized S. Randell, UNC
KK Bronchial cells H F508del CFTR hTERT /SV40 LT f 150 Immortalized S. Randell, UNC
CFT43 Airway cells H F508del CFTR SV40 LT 100–200 Immortalized J. Yankaskas, UNC
CFT1, Airway cells H F508del CFTR E6/E7 400–500 Immortalized J. Yankaskas, UNC
MDCK GFP-CFTR MDCK D wt CFTR f 300 GFP-CFTR N-term. Fusion B. Stanton, Dartmouth
MDCK GFP-DFCFTR MDCK D F508del CFTR f 300 GFP-CFTR N-term. Fusion B. Stanton, Dartmouth
JME/CF15 CF airway SV40 large T 200–1000 D. Jefferson, Tufts
A6 Xenopus kidney X ENaC, CFTR 1000–2000 ATCC
M1 Mouse kidney ENaC 1000–2000 ENaC expressing ATCC
mCT1-CF Collecting tubule M CFTR  / H-2Kb-tsA58 200–500 Temperature sensitive
transformed mouse cells
C. Cotton, Case Western
Reserve University
CFNPE14o- CF nasal polyp Nasal polyp
epithelial cells
H F508del/F508del pSVori-plasmid unknown Immortalized, +/
tight junctions
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFSMEo- CF submucosal
gland enriched
Submucosal gland
epithelial cells
H F508del/Q2X pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
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6CFSMEo- CF submucosal
gland enriched
Submucosal gland
epithelial cells
H F508del/Q2X pSVori-plasmid no Immortalized, subclone
of CFSMEo-
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFNPE9o- CF nasal polyp Nasal polyp
epithelial cells
H ?/? pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFDEo- CF airway Tracheobronchial
epithelial cells
H ?/? pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFBE45o- CF bronchus,
right upper lobe
Bronchial epithelial
cells
H F508del/R117H pSVori-plasmid unknown Immortalized, +/
tight junctions, male
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFBE46o- CF bronchus Bronchial epithelial
cells
H R117H/? pSVori-plasmid unknown Immortalized, tight
junction (?)
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
56FHTE8o- Fetal trachea Tracheobronchial
epithelial cells
H WT pSVori-plasmid unknown Immortalized, tight
junction (?)
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
mTEC1-CF Trachea Tracheobronchial
epithelial cells
M CFTR  / H-2Kb-tsA58 f 100 Temperature sensitive
transformed mouse cells
C. Cotton, Case Western
Reserve University
mPEC1-CF Pancreas Pancreatic epithelial
cells
M CFTR  / H-2Kb-tsA58 80–180 Temperature sensitive
transformed mouse cells
C. Cotton, Case Western
Reserve University
mSEC1-CF Salivary gland Salivary gland
epithelial cells
M CFTR  / H-2Kb-tsA58 250–400 Temperature sensitive
transformed mouse cells
C. Cotton, Case Western
Reserve University
16HBE14o- Normal bronchus,
1st bifurcation
Bronchial epithelial
cells
Endogenous
WT CFTR
pSVori-plasmid 200–1000 Immortalized. Tight
junctions, male
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFBE41o- CF bronchus,
1st bifurcation
Bronchial epithelial
cells
H F508del/F508del pSVori-plasmid 100–500 Immortalized, tight
junctions
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFTE29o- CF trachea Tracheobronchial
epithelial cells
H F508del/F508del pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
1HAEo- Airway Tracheobronchial
epithelial cells
H WT pSVori-plasmid 100–1000 Immortalized, tight junctions,
mucin expression
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
HSME6o- Submucosal
gland enriched
Submucosal gland
epithelial cells
H WT pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
HSME82o- Submucosal
gland enriched
Submucosal gland
epithelial cells
H WT pSVori-plasmid no Transformed/immortalized (?) D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
9HTEo- Trachea Tracheobronchial
epithelial cell
H WT pSVori-plasmid no Immortalized D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
HTE67tsa209o- Trachea Tracheobronchial
epithelial cell
H WT tsa209 plasmid no Immortalized, temperature
sensitive transformant
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
CFDEo-/6REP-CFTR CF airway Tracheobronchial
epithelial cell
H WT-CFTR,
RVS promoter
pSVori-plasmid no Immortalized, transfected
with a an episomal vector
pREP-CFTR4.7
D.C. Gruenert, Cal. Pacific
Med. Cent. Res. Inst.
MM-39 Submucosal
gland enriched
Sero/mucous
epithelial cells
H WT SV40 virus unknown Immortalized, express serous
cell markers and MUC genes
C Figarella, Marseille, FR
CF-KM4 Submucosal
gland enriched
Serous epithelial
cells
H F508del/F508del SV40 virus unknown Immortalized C Figarella, Marseille, FR
CFI-3 Fetal intestine Intestinal
epithelial cells
H S549N/N1303K pSVori-plasmid unknown Transformed C Gespach, Paris, FR
CFT-1 Fetal trachea Tracheobronchial
epithelial cell
H S549N/N1303K pSVori-plasmid unknown Transformed C Gespach, Paris, FR
CFT-3 Fetal trachea Tracheobronchial
epithelial cell
H F508del/F508del pSVori-plasmid unknown Transformed C Gespach, Paris, FR
BEAS 2B Bronchus Bronchial
epithelial cell
H WT AdV 12/SV40 no Immortalized CC Harris, LHC, NIH
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D.C. Gruenert et al. / Journal of Cystic Fibrosis 3 (2004) 191–196194Transformation and immortalization of airway epithelial
cells is an important asset and provides some very useful
tools for the study of airway diseases such as CF. However,
it is important to remember the limitations of this system
when making extrapolations to the epithelium in situ. The
first point to be emphasized is that the clones of cells
isolated are derived from a mixed population of primary
epithelial cells that have distinct phenotypic characteristics.
Therefore, an isolated clone represents a subpopulation of
the primary culture that can, but may not always, express
phenotypic characteristics of the principal cell-type of
origin. In addition, just as putting cells into primary culture
can alter the expression of cell-specific differentiated char-
acteristics, the process of transformation can also influence
the expression of differentiated features. Features such as
cell polarity and tight junction formation, secretion of
mucins, and formation of cilia can be demonstrated in a
number of clones, but these features are cell line-specific
and are not generally manifested in every clone. Some cell
lines will also change their phenotype over the course of
multiple passages, but this is often the result of growing the
cells on plastic rather than on a defined extracellular matrix.
Another element that may influence the expression and the
maintenance of specific differentiated endpoints over time
and/or multiple subcultures is the karyotypic instability
associated with the immortalized cells. In the early stages
of transformation that lead to immortalization, the cells are
generally ‘‘near diploid’’. This appears to be the case with
all of the transformation systems for epithelial cells includ-
ing the hTERT/SV40 T-antigen system. However, as the
cells become immortalized they become more aneuploid and
as a result more karyotypically unstable. This feature of the
cells could lead to the emergence of subpopulations that do
not retain the phenotypic endpoints of interest. The key to
selecting an immortalized cell line, for any study, depends
on the biological end points that are to be evaluated.
Nevertheless, the dependence of these end points on the
cellular context (i.e. background of relevant interacting
protein expression pattern) can not always be regulated.
In addition, the establishment of lymphoblastoid cell
lines has contributed to both the genetic and functional
characterization of CF. The development of lymphoblastoid
cell lines is an ideal archival resource for genetic and, in
some cases, functional information relevant to our under-
standing of CF [11]. As we gain further insight into
mechanisms underlying CF pathology, these lymphoblas-
toid cell lines may also provide important information about
the immunological responses to infection.2. EBV transformation of B-lymphocytes
The generation of immortalized lymphoblastoid cells
lines from peripheral blood lymphocytes (B-lymphocytes)
can be successfully accomplished by infecting the cells with
Epstein-Barr virus (EBV) [12,13]. These lymphoblastoidcells can then be used as a source of DNA or RNA to study
various genes, specific genetic defects, and the transcripts of
the genes being studied. For this purpose one needs (1)
purified leukocytes (white blood cells), (2) a source of EBV,
and (3) a means to preferentially infect the B-lymphocytes,
while suppressing the growth of the T lymphocytes present
in the preparation. The virus production should be done in a
facility that has the infrastructure to contain virus spread.
Once the cells are transfected, no special precautionary
measures are required to handle them, except standard tissue
culture methods. The overall majority of people have been
exposed to EBV. Nevertheless, it is not recommended to
transform B cells from persons working in the same
laboratory.3. Production of EBV supernatants for lymphocyte
transformation
Monkey B95-8 cells (EBV producers) are grown at
0.25–1106 cells per ml as suspension cultures in T-25
flasks in 20 ml DME/F12 supplemented with 10% FCS; and
split regularly to obtain sufficient supernatant. When cul-
tures are saturated, they are transferred to T-175 flasks with
40 ml medium. Falcon flasks are left undisturbed for 5 days.
The supernatant is removed, spun at 2000 rpm for 10 min
and clarified with a 0.45-Am filter. After quickly freezing
and thawing three times to disrupt the cells and release the
virus, the supernatant is placed in ampuoles (2 ml/ampoule)
and stored by freezing in liquid nitrogen. About 2 ml of
supernatant is required for one transformation, but volumes
can be adapted as needed. The supernatants remain active
for years when frozen.4. Purification of lymphocytes from peripheral blood
Peripheral blood is purified by centrifugation in Accus-
pin 1077 tubes (separation gel containing tubes) at 2500
rpm for 30 s at room temperature. Heparinized fresh blood
(3–6 ml) is layered on top of the filter on the Accuspin tube
and then centrifuged at 2500 rpm for 15 min at room
temperature. If the separation is not clear or clean, repeat
centrifugation may be necessary. The possible cause of a
preparation that is nor clear is old or cold blood. When the
blood is too old, no separation is achieved. After centrifu-
gation, the plasma is carefully removed with a pipette up to
a point f 0.5 cm above the opaque, cell containing band.
The cells are transferred to a 15-ml tube, washed with
physiological saline (0.9% NaCl), and centrifuged at 1200
rpm for 15 min and at 4 jC. The pellet is again washed with
saline and centrifuged at 800 rpm for 10 min and at 4 jC.
Cells are resuspended in 8 ml medium (RPMI 1640 or
DMEM/Hams F12 1/1 + 10% Fetal Calf Serum) with 2 Ag/
ml cyclosporine. The cell culture is started in T25 Falcon
flasks maintained upright (4 ml/flask and 1 ml EBV
D.C. Gruenert et al. / Journal of Cystic Fibrosis 3 (2004) 191–196 195supernatant is added to each flask). After weeks 1 and 2,
about 2 ml of medium is added to each flask, respectively.
The cultures are checked two times a week for cell growth
(clump formation) and fresh medium is added as needed. As
the number of clumps and clump size increases (generally
after f 4 weeks), the cells can be subcultured by transfer-
ring half the volume to another flask. An aliquot of the cells
are then analyzed for their karyotype and the remaining
culture is cryopreserved with f 106 cells in 2 ml DMEM-
F12 + 15% FCS + 5% DMSO/ampoule (5 ampoules/patient).5. Transformation and immortalization of airway
epithelial cells
The transformation and immortalization of airway epi-
thelial cells is relatively routine, but it is important to pay
attention to certain details of the cultured primary epithelial
cells to optimize the potential for generating a cell line that
can go from an enhanced growth character to ultimate
immortalization. This is clearly important when airway cell
samples are rare, especially for specific mutations. The
following principals apply generally regardless of the trans-
formation protocol or reagents used. However, the details of
transformation and immortalization via and origin-of-repli-
cation defective SV40 plasmid will be discussed here.
The condition of the primary culture before transfection
is critical for the development of cell lines. If the cells are
too sparse or have been subcultured >4 times the potential
for generating viable, long-lived clones of cells decreases
dramatically. It is also important to avoid growing the cells
in medium that contains agents such as retinoic acid or
serum that will promote terminal differentiation of the
primary culture. Generally, the best time to transfect the
primary cells is after subculturing and when the cells are still
in logrithmic growth (this usually corresponds to 70–80%
confluence). The cells can then be incubated in the presence
of a serum free, hypotonic (5.5:6.0, medium: H2O) medium
and the plasmid/transfection complex. Various chemical
compounds including calcium phosphate (CaPO4), stron-
tium phosphate (SrPO4), lipofectamine, and SUPERFECT
as well as physical transfection procedures like electro-
poration have been successfully used to introduce the trans-
forming, pSVori-plasmid into the cells [14]. Naturally, if
viral vectors are used, this transfection protocol is modified
to accommodate infection of the cells, but the culture
conditions will still need to be monitored.
After an incubation period of 4–5 h with the transfection
complex, the medium is removed and cells are thoroughly
rinsed to remove any transfection complex that may have
precipitated onto the cells or the culture dish. This washing
procedure is of critical importance to ensuring that the
transfected cultures maintain their proliferative potential.
After washing, the cells are grown for at least 24 h in
complete serum-free-growth medium. The cells can then be
grown to confluence and maintained until the culturessenesce and colonies of proliferating cells emerge. Alterna-
tively, the cells can be subcultured within 24–48 h post-
transfection, grown to confluence and maintained until
proliferating colonies emerge. Colonies of proliferating cells
(>100 cells/colony) are then isolated using cloning rings and
subcultured into 6 well plates.6. Conclusion
The development of immortalized cell lines has been
critical to enhancing our understanding of the physiological,
biochemical and genetic mechanisms underlying CF and for
the development of therapeutic strategies designed to man-
age CF pathology. The key to selecting an immortalized cell
line, for any study, depends on the biological end points that
are to be evaluated. Nevertheless, the dependence of these
end points on the cellular context can not always be
regulated.
Not only have epithelial cells played a critical role in
advancing our understanding of CF and its treatment, but
lymphoblastoid cell lines have also contributed to both the
genetic and functional characterization of CF, as a source of
DNA or RNA and as an archival resource for future genetic
studies. All the techniques and cell lines described here can
be found in detail at the European Working Group on CFTR
Expression website [15].References
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